Mumbai: Maharashtra Chief Minister Eknath Shinde and Deputy Chief Minister Devendra Fadnavis inaugurated Phase 2A of Mumbai Metro Line 3 on Friday, marking a significant milestone in the city’s ...

These version 3.3 Phase 1 Banners start on Wednesday 21st May and are expected to end on Wednesday 11th June. These version 3.3 Phase 2 Banners are expected to run from Wednesday 11th June to ...

no evidence of lymphopenia or CD4 cell count reduction was observed with the islatravir component. Only 2% to 3% of patients discontinued due to adverse events, indicating good tolerability.

In a big leap for Mumbai’s public transport, Metro Line 3's second phase—connecting Bandra-Kurla Complex (BKC) to Acharya Atre Chowk in Worli—officially began operations on Saturday ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in itching that began after two weeks and persisted through the 24-week primary ...

I look forward to helping advance the OVATION 3 trial and seeing the results.” The Phase 3 OVATION 3 trial will assess the safety and efficacy of IMNN-001 (100 mg/m 2 administered intraperitoneally ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

Braintree ® intends to submit results from the TRIUMpH Phase 3 studies to a high impact, peer reviewed journal along with presentation of this data at a leading gastroenterology conference in the ...

Claim your 7-day free trial now. Eli Lilly And Co LLY stock is trading higher on Thursday after the U.S. healthcare giant reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron ...

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...

A phase 3 trial in metastatic melanoma is ongoing, with a Biologics License Application expected by year-end. The vaccines offer a novel approach by targeting the entire tumor environment ...

Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in ...